Iperplasin (Mepartricin)

Mepartricin acts by modulating inflammatory pathways within prostatic tissue, decreasing cytokine release, and inhibiting fibroblast activity. This results in reduced collagen deposition and fibrosis, leading to decreased swelling of the prostate and relief of urinary symptoms.

The specific dosage of Iperplasin is determined by the prescribing healthcare professional based on the patient’s condition, severity, and overall health status. Patients should follow the prescriber’s instructions and not alter the dose without medical guidance.

Safety data for Mepartricin in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and it is not recommended for breastfeeding mothers because excretion in milk is unknown.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Iperplasin. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Iperplasin’s unique anti‑inflammatory and anti‑fibrotic mechanism differentiates it from alpha‑blockers or 5‑alpha‑reductase inhibitors, which primarily target smooth‑muscle tone or hormonal pathways. It may be used as an adjunct or alternative when inflammation and fibrosis are predominant contributors to symptoms.

Iperplasin should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Iperplasin is administered orally, typically as a tablet taken with water. The exact timing (e.g., with meals or on an empty stomach) should follow the prescribing clinician’s recommendations.

Serious risks, although rare, include severe allergic reactions such as rash, urticaria, or anaphylaxis, hepatic dysfunction indicated by elevated liver enzymes, and hematologic abnormalities like neutropenia or thrombocytopenia. Patients should seek immediate medical attention if any of these occur.

Iperplasin is contraindicated in patients with known hypersensitivity to Mepartricin or any excipients in the formulation. Caution is also advised for individuals with severe liver or kidney impairment, pregnant or breastfeeding women, and those taking medications that may interact significantly without proper monitoring.